tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

PFE Stock Latest News

Pfizer (NYSE:PFE) Will Not Slash Prices for Xtandi
Market NewsPfizer (NYSE:PFE) Will Not Slash Prices for Xtandi
2d ago
PFE
Pyxis Oncology discloses $5M purchase of common stock by Pfizer
The FlyPyxis Oncology discloses $5M purchase of common stock by Pfizer
3d ago
PFE
PYXS
FDA moving towards authorizing second omicron booster, WSJ reports
The FlyFDA moving towards authorizing second omicron booster, WSJ reports
3d ago
PFE
BNTX
Seagen price target raised to $229 from $145 at TD Cowen
The FlySeagen price target raised to $229 from $145 at TD Cowen
3d ago
PFE
SGEN
Seagen price target raised to $229 from $152 at Truist
The FlySeagen price target raised to $229 from $152 at Truist
4d ago
PFE
SGEN
Pfizer Stock (NYSE:PFE): Exceptional Value Near 52-Week Lows
Stock Analysis & IdeasPfizer Stock (NYSE:PFE): Exceptional Value Near 52-Week Lows
7d ago
PFE
Pfizer price target lowered to $44 from $50 at Wells Fargo
The FlyPfizer price target lowered to $44 from $50 at Wells Fargo
7d ago
PFE
Astellas Pharma / Pfizer announce positive results from Embark trial of XTANDI
The FlyAstellas Pharma / Pfizer announce positive results from Embark trial of XTANDI
8d ago
PFE
Pfizer says continues to gather pediatric data on Paxlovid
The FlyPfizer says continues to gather pediatric data on Paxlovid
8d ago
PFE
FDA advisory committee votes in support of safety and effectiveness of Paxlovid
The FlyFDA advisory committee votes in support of safety and effectiveness of Paxlovid
8d ago
PFE
FDA advisors back full approval for Pfizer’s Paxlovid in 16-1 vote
The FlyFDA advisors back full approval for Pfizer’s Paxlovid in 16-1 vote
8d ago
PFE
Pfizer recalls Nurtec ODT on packaging issues, risk of poisoning
The FlyPfizer recalls Nurtec ODT on packaging issues, risk of poisoning
8d ago
PFE
Royalty Pharma raises FY23 adjusted cash receipt guidance to $2.85B-$2.95B
The FlyRoyalty Pharma raises FY23 adjusted cash receipt guidance to $2.85B-$2.95B
9d ago
PFE
RPRX
Seagen downgraded to Equal Weight from Overweight at Morgan Stanley
The FlySeagen downgraded to Equal Weight from Overweight at Morgan Stanley
9d ago
PFE
SGEN
Pfizer’s deal in EU for Covid-19 vaccine meets some resistence, FT says
The FlyPfizer’s deal in EU for Covid-19 vaccine meets some resistence, FT says
10d ago
PFE
JPMorgan biotech/pharma analysts to hold analyst/industry conference call
The FlyJPMorgan biotech/pharma analysts to hold analyst/industry conference call
10d ago
PFE
SGEN
JPMorgan biotech/pharma analysts to hold analyst/industry conference call
The FlyJPMorgan biotech/pharma analysts to hold analyst/industry conference call
10d ago
PFE
SGEN
Seagen price target raised to $229 from $155 at RBC Capital
The FlySeagen price target raised to $229 from $155 at RBC Capital
10d ago
PFE
SGEN
Seagen price target raised to $229 from $141 at SVB Securities
The FlySeagen price target raised to $229 from $141 at SVB Securities
10d ago
PFE
SGEN
Seagen price target raised to $229 from $210 at Oppenheimer
The FlySeagen price target raised to $229 from $210 at Oppenheimer
10d ago
PFE
SGEN
Seagen price target raised to $228 from $145 at Barclays
The FlySeagen price target raised to $228 from $145 at Barclays
10d ago
PFE
SGEN
Seagen downgraded to Market Perform from Outperform at JMP Securities
The FlySeagen downgraded to Market Perform from Outperform at JMP Securities
10d ago
PFE
SGEN
Seagen downgraded to Market Perform from Outperform at BMO Capital
The FlySeagen downgraded to Market Perform from Outperform at BMO Capital
11d ago
PFE
SGEN
Needham downgrades Seagen, says competing bid unlikely
The FlyNeedham downgrades Seagen, says competing bid unlikely
11d ago
PFE
SGEN
Pfizer Snaps Up Seagen for $43B
Market NewsPfizer Snaps Up Seagen for $43B
11d ago
PFE
SGEN
Pfizer to acquire Seagen for $229 per share in cash
The FlyPfizer to acquire Seagen for $229 per share in cash
11d ago
PFE
SGEN
Pfizer announces FDA approval of ZAVZPRET
The FlyPfizer announces FDA approval of ZAVZPRET
14d ago
PFE
Jefferies starts Pfizer with a Hold on lack of visibility
The FlyJefferies starts Pfizer with a Hold on lack of visibility
18d ago
PFE
Pfizer initiated with a Hold at Jefferies
The FlyPfizer initiated with a Hold at Jefferies
18d ago
PFE
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.